Research and Markets: Cancer Stem Cells Drug Pipeline Update 2013

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/82v6t2/cancer_stem_cells) has announced the addition of the "Cancer Stem Cells Drug Pipeline Update 2013" report to their offering.

Treatments designed to target and destroy cancer stem cells may come to revolutionize how we treat cancer. This unique product covers both explicit cancer stem cell drug development and cancer drugs which are inhibitors of the Hedgehog, Notch, and WNT Pathway. These developmental pathways are frequently activated in neoplasms, and particularly in the rare subpopulation of cancer stem cells.

There are today 308 companies plus partners developing 478 cancer stem cells and developmental pathways drugs in 1568 developmental projects in cancer. In addition, there are 6 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 232 drugs. Cancer Stem Cells Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 257 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 250 out of the 253 studied drug targets so far have been recorded with somatic mutations.

All drugs targets are further categorized on in the software application by 49 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

Reasons to Buy

Pipeline Breakdown According to Number of Drugs

For more information visit http://www.researchandmarkets.com/research/82v6t2/cancer_stem_cells

See the original post:
Research and Markets: Cancer Stem Cells Drug Pipeline Update 2013